FDA Brief

Warning letters Drugs

FDA warning letter to

Biotek India

High riskIssued May 13, 2021Posted May 25, 2021Center for Drug Evaluation and Research

Biotek India, an OTC drug maker, lacked active-ingredient testing and sold an unapproved 99% isopropyl rubbing alcohol.

What happened

FDA did not inspect. Instead, it reviewed records Biotek India submitted after FDA's April 21, 2020 request for records under section 704(a)(4) of the Food, Drug, and Cosmetic Act, which lets FDA demand records instead of visiting. The records showed no finished-product testing for identity and strength of active ingredients, no identity testing of incoming raw materials, and stability data that did not test the active ingredient or microbiology. FDA also found the company's U 99% Isopropyl Rubbing Alcohol is an unapproved new drug, because 99% is above the 50-91.3% range proposed in the 1991 tentative final monograph for first aid antiseptics.

What FDA found

  1. The company released drug batches to the U.S. without testing that each batch met final specifications, including identity and strength of the active ingredient.

    21 CFR 211.165(a)
  2. The company did not run at least one identity test on each incoming raw material used to make its drugs.

    21 CFR 211.84(d)(1)
  3. The stability program was inadequate: the data did not test the active ingredient or microbiological quality, so shelf life was not supported.

    21 CFR 211.166(a)
  4. U 99% Isopropyl Rubbing Alcohol was sold as a first aid antiseptic without FDA approval, making it an unapproved new drug.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  5. The product is misbranded because 99% isopropyl alcohol does not meet the conditions for marketing a nonprescription drug without approval.

    Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)

What FDA wants

FDA tells Biotek India to answer in writing within 15 working days with a full testing plan, retain-sample results, an independent review of its laboratory and material systems, and a remediated stability program, and warns that products may be recalled if testing shows substandard quality. FDA also strongly recommends hiring a qualified CGMP consultant to audit the whole operation.

Who should pay attention

  • U.S. distributors and retailers selling imported OTC antiseptics and rubbing alcohol
  • brands that buy finished OTC drugs from Indian contract manufacturers
  • quality teams that accept supplier certificates of analysis instead of testing each lot

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk